Adeptio Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe, Austedo (deutetrabenazine) / Teva
    Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Valbenazine and Deutetrabenazine (Grand Saguaro) -  Oct 31, 2022 - Abstract #ACNP2022ACNP_890;    
    Deutetrabenazine is metabolized to 4 deuHTBZ stereoisomers, the most abundant of which ([-]-α-deuHTBZ) has negligible interaction with VMAT2 in vitro and appreciable affinity for several off-target receptors- these findings were similar to what has been reported for tetrabenazine. Based on relative potency and abundance, [+]-β-deuHTBZ appears to be the primary contributor to VMAT2 inhibition of deutetrabenazine.
  • ||||||||||  (+)-α-dihydrotetrabenazine (ADE 513) / Adeptio Pharma, Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe, Austedo (deutetrabenazine) / Teva
    Relationship Between Interleukin-6 (IL-6) Blood Levels and Treatment Outcome in Patients With Treatment-Resistant Bipolar Disorder Depression (TRBDD) (Grand Saguaro) -  Oct 31, 2022 - Abstract #ACNP2022ACNP_308;    
    Deutetrabenazine is metabolized to 4 deuHTBZ stereoisomers, the most abundant of which ([-]-α-deuHTBZ) has negligible interaction with VMAT2 in vitro and appreciable affinity for several off-target receptors- these findings were similar to what has been reported for tetrabenazine. Based on relative potency and abundance, [+]-β-deuHTBZ appears to be the primary contributor to VMAT2 inhibition of deutetrabenazine.
  • ||||||||||  (+)-?-dihydrotetrabenazine (ADE 513) / Adeptio Pharma
    Trial completion:  (+)-Alpha-Dihydrotetrabenazine Phase I (clinicaltrials.gov) -  Aug 22, 2017   
    P1,  N=6, Completed, 
    Based on relative potency and abundance, [+]-β-deuHTBZ appears to be the primary contributor to VMAT2 inhibition of deutetrabenazine. Recruiting --> Completed
  • ||||||||||  (+)-?-dihydrotetrabenazine (ADE 513) / Adeptio Pharma
    Trial primary completion date:  (+)-Alpha-Dihydrotetrabenazine Phase I (clinicaltrials.gov) -  Mar 28, 2017   
    P1,  N=6, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Dec 2016 --> Jul 2017
  • ||||||||||  (+)-?-dihydrotetrabenazine (ADE 513) / Adeptio Pharma
    Enrollment open:  (+)-Alpha-Dihydrotetrabenazine Phase I (clinicaltrials.gov) -  Aug 24, 2016   
    P1,  N=6, Recruiting, 
    Trial primary completion date: Dec 2016 --> Jul 2017 Not yet recruiting --> Recruiting
  • ||||||||||  (+)-?-dihydrotetrabenazine (ADE 513) / Adeptio Pharma
    New P1 trial:  (+)-Alpha-Dihydrotetrabenazine Phase I (clinicaltrials.gov) -  Jul 27, 2016   
    P1,  N=6, Not yet recruiting,